COYA · Coya Therapeutics, Inc.
Market Cap
$98.52M
Shares
23.46M
Volume · Oct 20
34.79K
Avg daily vol (3M)
140.25K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$4.20
Open$4.29
Day$4.20–4.54
52W close$3.78–7.36
Avg vol 30d152K
Short int1.2M · 5.1% float · 7.0d
Short vol50%
Last earningsJun 2, 2026
DataDec 2022–Oct 2026
Filing10-Q · Aug 11
Up next
filed Aug 11, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$8.02M
Trailing 12 months
Net income (TTM)
−$21.67M
Trailing 12 months
Revenue growth YoY
+49.0%
Year over year
Operating margin
-288.7%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$43.18M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+40.3%
Year over year · more shares
Price change (1Y)
-34.0%
Trailing year
Short interest
5.1%
Latest settlement · 7.0 days to cover
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Bearish
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 18.4 · elevated
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−10%
below
Price vs 50-day avg
−12%
below
RSI (14)
36
neutral
MACD trend
Negative
52-week position
12%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−15%
trailing
6-month return
−1%
trailing
YTD return
−28%
this year
Relative strength
−9%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $5 › 200d $5 — 50d above 200d
Institutional flow
Distributing
3 of 55 funds reported for Sep 30 · net -2.0K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
5.08% of float · ▲ +0.3% MoM · 7.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
55 holders — mid 3-yr range
Squeeze score
67
elevated · 0–100
Fundamentals
Revenue growth
+124%
Y/Y
EPS growth
−30%
Y/Y
Quant / Vol
risk profile
Volatility
62%
annualized · 1-yr
Max drawdown
−49%
past year
ATR
6.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−10%
Bearish
Price vs 50-day avg
−12%
Bearish
RSI (14)
36
Neutral
MACD trend
Negative
Bearish
52-week position
12%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $5 › 200d $5 — 50d above 200d
Institutional flow
Distributing
3 of 55 funds reported for Sep 30 · net -2.0K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
5.08% of float · ▲ +0.3% MoM · 7.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
55 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $4
Now $4 · 12%
Range high $7
vs 200-day avg -10%
vs 50-day avg -12%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
COYA
this stock
Coya Therapeutics, Inc.
|
$98.52M | -27.6% | +123.6% | — | 5.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.07B | +10.7% | +46.2% | 29.9 | 1.8% |
|
MRNA
Moderna, Inc.
|
$90.58B | +669.4% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$80.51B | +1.3% | +20.8% | 19.4 | 2.1% |
|
CSLLY
Csl Ltd
|
$64.50B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
SEC Filings
Latest
8-K
- Filed
- Oct 14, 2026
- This year
- 20
Coya Therapeutics, Inc. plans to begin the Phase 2/3 ALSTARS Trial open-label extension in November 2026, while shifting the planned COYA 302 frontotemporal dementia Phase 2 trial to 2027; cash runway remains into the second half of 2027.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| COYA | -12.7% | -15.2% | -1.4% | -16.2% | -27.6% |
| SPY | -1.5% | -0.9% | +7.7% | +0.5% | +12.4% |
| vs SPY | -11.2% | -14.2% | -9.1% | -16.7% | -40.0% |